Business Services Industry

Supporters Say Public-Private Funding Is Best Bet for Biotechnology Research.

Knight Ridder/Tribune Business News, August, 2001

By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News

Aug. 15--A decade ago, Therion Biologics Corp. set out to create a host of vaccines -- some to prevent the spread of AIDS, others to fight various cancers -- on just $3 million from private investors.

Over the years, the Cambridge biotechnology company raised another $30 million in private funding. But investors were reluctant to fund HIV and cancer vaccines, research areas fraught with failure and risk, and each dollar was hard won.

So Therion joined the small but growing ranks of companies that rely on public money to support their research efforts. It received $15 million for its AIDS vaccine program from the National Institutes of Health. And it struck research deals with...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement